NCT06112340: A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) |
|
|
| Recruiting | 2b | 75 | US | linsitinib | Sling Therapeutics, Inc. | Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto | 06/26 | 06/26 | | |
2021-005000-36: Study to Evaluate the Safety and Efficacy of Linsitinib in Patients with Active, Moderate to Severe Thyroid Eye Disease Estudio para evaluar la seguridad y eficacia del linsitinib en pacientes con enfermedad ocular tiroidea (EOT) activa y de moderada a grave. |
|
|
| Ongoing | 2 | 75 | Europe | Linsitinib, ASP7487, OSI-906, Film-coated tablet | VasaraGen, Inc., VasaraGen Inc. | Thyroid eye disease (TED) Enfermedad Ocular Tiroidea (EOT), Thyroid eye disease Enfermedad Ocular Tiroidea, Diseases [C] - Eye Diseases [C11] | | | | |